CDX 3379

Drug Profile

CDX 3379

Alternative Names: KTN 3379

Latest Information Update: 01 Dec 2016

Price : $50

At a glance

  • Originator MedImmune
  • Developer Celldex Therapeutics Inc
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action ERBB-3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Head and neck cancer; Solid tumours; Thyroid cancer

Most Recent Events

  • 29 Nov 2016 Kolltan Pharmaceuticals has been acquired and merged into Celldex Therapeutics Inc
  • 29 Nov 2016 Celldex Therapeutics completes the phase Ib portion of a phase I trial in Solid tumours (Combination therapy, Late-stage disease, Monotherapy)
  • 06 Jun 2016 Updated efficacy, safety and pharmacokinetics data from the phase Ib trial in Solid tumours presented at the 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top